A61K47/61

Hyaluronan conjugates and uses thereof
11524079 · 2022-12-13 · ·

Disclosed herein is a hyaluronan conjugate, which includes a hyaluronic acid (HA), a sex hormone, and a linker for coupling one of the disaccharide units of the HA and the sex hormone. Also disclosed herein are the uses of the hyaluronan conjugate in treating or preventing neurodegenerative diseases.

NANOSTRUCTURED DRUG DELIVERY SYSTEM AS A MULTIFUNCTIONAL PLATFORM FOR THERAPY

The present invention discloses a drug delivery system for targeted therapy comprising a functionalized lipid-based nanoplatform, where at least one ligand is coupled to the surface of the nanoplatform and encapsulates at least one pharmaceutically active ingredient. A process for obtaining the drug delivery system of the present invention is also disclosed as well as a composition comprising the system of the invention. The invention relates to the field of medicine and biotechnology. The present solution aims at developing targeting co-encapsulating nanostructured lipid carriers for the treatment of different types of cancer, including glioblastoma, as well as other diseases and disorders, envisioning the establishment of an in vitro/in vivo correlation.

NANOSTRUCTURED DRUG DELIVERY SYSTEM AS A MULTIFUNCTIONAL PLATFORM FOR THERAPY

The present invention discloses a drug delivery system for targeted therapy comprising a functionalized lipid-based nanoplatform, where at least one ligand is coupled to the surface of the nanoplatform and encapsulates at least one pharmaceutically active ingredient. A process for obtaining the drug delivery system of the present invention is also disclosed as well as a composition comprising the system of the invention. The invention relates to the field of medicine and biotechnology. The present solution aims at developing targeting co-encapsulating nanostructured lipid carriers for the treatment of different types of cancer, including glioblastoma, as well as other diseases and disorders, envisioning the establishment of an in vitro/in vivo correlation.

GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES

The present disclosure relates to glyconucleic acids, such as glycoRNA and glycoDNA described herein. Provided are glycosylated ribonucleic acid (glycoRNA)-related methods and compositions.

GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES

The present disclosure relates to glyconucleic acids, such as glycoRNA and glycoDNA described herein. Provided are glycosylated ribonucleic acid (glycoRNA)-related methods and compositions.

METHOD OF PROMOTING CELLULAR HYDRATION BY ENHANCING INTRACELLULAR PERMEATION
20220378774 · 2022-12-01 · ·

A method of promoting increased cellular hydration in a multicellular organism that is capable of intracellular water permeation includes the step of causing the multicellular organism to ingest an aqueous solution that contains an amount of a carbohydrate clathrate component. There is also a step of enhancing the intracellular permeation. The multicellular organism contains aquaporins, and the causing step involves interaction of the composition with the aquaporins. The cellular hydration promoted and caused by the method is corroborated by a test that uses human-aquaporin-expressed frog oocytes. The test uses single cell Xenopus laevis frog oocytes having expressed human aquaporin AGP1 water channels. There is also a beverage composition that increases lifespan in the multicellular organism, and a beverage composition that promotes cellular hydration when ingested by a multicellular organism.

METHOD OF PROMOTING CELLULAR HYDRATION BY ENHANCING INTRACELLULAR PERMEATION
20220378774 · 2022-12-01 · ·

A method of promoting increased cellular hydration in a multicellular organism that is capable of intracellular water permeation includes the step of causing the multicellular organism to ingest an aqueous solution that contains an amount of a carbohydrate clathrate component. There is also a step of enhancing the intracellular permeation. The multicellular organism contains aquaporins, and the causing step involves interaction of the composition with the aquaporins. The cellular hydration promoted and caused by the method is corroborated by a test that uses human-aquaporin-expressed frog oocytes. The test uses single cell Xenopus laevis frog oocytes having expressed human aquaporin AGP1 water channels. There is also a beverage composition that increases lifespan in the multicellular organism, and a beverage composition that promotes cellular hydration when ingested by a multicellular organism.

TOUGH TISSUE SEALANTS AND THE USE THEREOF

The invention provides injectable, tough hydrogels that can be crosslinked in situ on demand using minimally-invasive methods, such as visible light exposure is an unmet medical challenge. Among the emerging biopolymers for tissue sealing, gelatin methacryloyl (GelMA), a naturally-derived biopolymer obtained from denatured collagen, has secured a promising role as a result of its excellent bioadhesion, biodegradation, and biocompatibility. To overcome one of the main shortcomings of GelMA, i.e., brittleness, we hybridized it using methacrylate-modified alginate (AlgMA) to impart ion-induced reversible crosslinking that can dissipate energy under strain. The hybrid GelMA-AlgMA hydrogels provide a photocrosslinkable, injectable, and adhesive platform with an excellent toughness that can be engineered using divalent cations, such as calcium. This class of novel hybrid biopolymers with more than 600% improved toughness may set the stage for durable, mechanically-resilient, and cost-effective tissue sealants in minimally invasive procedure, especially for stretchable tissues.

Hyaluronic acid derivative modified with polyethylene glycol

The present invention provides hyaluronic acid derivatives including one or more of each of repeating units represented by the formulae (Ia), (Ib), and (Ic) in which certain cationic sites, certain hydrophobic sites, and certain hydrophilic sites have been introduced. In addition, the present invention provides complexes of the hyaluronic acid derivatives with a drug and pharmaceutical compositions including the hyaluronic acid derivatives, in particular, complexes of the hyaluronic acid derivatives with a drug.

Hyaluronic acid derivative modified with polyethylene glycol

The present invention provides hyaluronic acid derivatives including one or more of each of repeating units represented by the formulae (Ia), (Ib), and (Ic) in which certain cationic sites, certain hydrophobic sites, and certain hydrophilic sites have been introduced. In addition, the present invention provides complexes of the hyaluronic acid derivatives with a drug and pharmaceutical compositions including the hyaluronic acid derivatives, in particular, complexes of the hyaluronic acid derivatives with a drug.